15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English Immunitor Awarded the Key U.S. Patent Related to Ora ...
查看: 1407|回复: 11
go

Immunitor Awarded the Key U.S. Patent Related to Oral Vaccine Technology Platfo [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2010-11-30 11:45 |只看该作者 |倒序浏览 |打印
本帖最后由 StephenW 于 2010-11-30 11:50 编辑

        

I am a little bit skeptical about this company and its therapeutic vaccine, V5. Readers should make their own judgment.关于这家公司和它的治疗性疫苗,V5, 我有点怀疑。读者应自行判断。


press release

                                                                        

  Nov. 29, 2010, 7:38 a.m. EST                                

  Immunitor Awarded the Key U.S. Patent Related to Oral Vaccine Technology Platform                        

               
        
        
         
        
                                                                                
VANCOUVER, British Columbia, Nov 29, 2010 (GlobeNewswire via COMTEX) --Immune Network Ltd.                  advises that its potential acquisition, Immunitor USA Inc., has been issued a key patent by the U.S. Patent and Trademark Office (USPTO).                                                               
The patent (US 7,838,006 "Viral vaccine composition, process and methods of use") contains claims covering the composition of matter for Immunitor's lead product, V5. The patent also covers the process of making and use of the matter for treating and preventing the broad range of infectious diseases.   Immunitor was previously awarded a U.S. patent covering another lead compound specifically designed for treatment of AIDS (US 7,384,637).                                                               
According to Vichai Jirathitikal, the principal inventor on these two patents, "The USPTO has validated the novelty and utility of Immunitor's technology and its use in the treatment and prophylaxis of a range of most diverse diseases and conditions." The co-inventor, Aldar Bourinbaiar, Immunitor's CEO, added: "With the issuance of these two patents, our lead programs are further protected, significantly enhancing their commercial value."                                                               
Over the course of the company's development, Immunitor has achieved a broad and deep intellectual-property position in the orally delivered immunotherapeutics area. The company's patent portfolio now includes more than eight pending patents (including two international), with at least two dozen scientific publications in the peer-reviewed medical literature describing various aspects of the technology in infectious and autoimmune diseases, cancer, and metabolic diseases such as atherosclerosis and obesity. The combined annual market for these and related indications is close to $100 billion.                                                               
Immunitor is the industry leader in tableted oral vaccines and immunotherapies. During the past three years Immunitor completed two phase II clinical trials using V5 for treatment of chronic hepatitis B and hepatitis C. This year Immunitor seized upon an unexpected clinical outcome, which revealed the intriguing potential of V5 in curing tuberculosis in almost 95% of patients within one month. The results of the first trial in patients with tuberculosis who were co-infected with hepatitis C virus and HIV were published in October issue of Journal of Vaccines and Vaccination (http://www.omicsonline.org/2157-7560/2157-7560-1-103.php). Patient enrollment for two additional phase 2b placebo-controlled trials involving 120 patients with difficult-to-treat forms of tuberculosis has been just completed in Ukraine and results are anticipated in early 2011.                                                               
To date, all clinical trials of V5 have provided strong evidence of an excellent safety profile and provided insights into the unparalleled efficacy that will guide Immunitor in the design of follow-on hepatitis and tuberculosis studies, which are now being arranged in South Africa, Pakistan, India and China.                                                               
Immune Network is continuing its work toward meeting the pre-conditions for completion of a merger or similar transaction with Immunitor. Several aspects of the updated corporation and its anticipated transactions will be announced early in December 2010.                                                               
A temporary website for Immune Network is at http://www.immune-network.com. The Immune Network Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8008 .                                                               
Safe Harbor Statement                                                               
The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.                                                               
This news release was distributed by GlobeNewswire, www.globenewswire.com                                                               
SOURCE: Immune Network Ltd                                                               
CONTACT:  Immune Network Ltd
[email protected]



(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.


新闻稿

2010年11月29日,美国东部时间上午07时38分
Immunitor荣获关键的美国专利有关的口服疫苗技术平台

温哥华,不列颠哥伦比亚省,2010年11月29日(通过COMTEX商业电讯) - 免疫网络有限公司/ ,其潜在的收购建议,Immunitor美国公司已经印发了美国专利和商标局(USPTO)的关键专利。

专利(美国7838006“病毒疫苗的成分,工艺和使用方法”)包含索赔涉及的物质为Immunitor的主导产品,V5的组成。该专利还包括制作和使用的物质用于治疗和预防传染病的范围广泛的过程。 Immunitor曾获得美国专利涉及另一个专门为先导化合物艾滋病(美国7384637)治疗而设计的。

据威猜Jirathitikal,关于这两项专利的主要发明者,“美国专利商标局已经验证了Immunitor的技术新颖性和实用性及其在治疗和最多样化的一系列预防疾病和条件使用。”共同发明人,Aldar Bourinbaiar,Immunitor的首席执行官补充说:“随着这两项专利的发行,我们的领先优势进一步保护方案,大大提高其商业价值。”

在公司的发展历程,取得了Immunitor在口服免疫疗法领域提供广泛而深入的知识产权地位。该公司的专利产品组合现在包括超过八待(其中包括两名国际)的专利,至少有两打在同行评审的医疗描述感染和自身免疫性疾病,癌症和代谢性疾病的技术的各个方面,如文学科学出版物动脉粥样硬化和肥胖症。合并后的这些年市场和相关的迹象已经接近1000亿美元。

Immunitor是口服疫苗和免疫疗法片状行业的佼佼者。在过去的三年Immunitor完成了两个阶段的II期临床试验中使用的慢性乙型肝炎和丙型肝炎的治疗,今年Immunitor V5的意外后,临床疗效,结果发现,治疗,几乎95%的患者肺结核的V5的耐人寻味的潜力检在一个月内。肺结核谁共与丙型肝炎病毒和艾滋病毒感染在10月的疫苗和疫苗接种杂志上(http://www.omicsonline.org/2157-7560/2157-7560公布的业绩,患者第一次审判- 1 - 103.php)。病人增设两个阶段第2B期安慰剂对照试验,涉及人数120例难以治疗结核病的形式已在乌克兰刚刚完成,结果是在2011年年初的预期。

迄今为止,V5的所有临床试验将提供无与伦比的效能,将指导在设计Immunitor有力的证据一个很好的安全性和提供的见解后续肝炎和肺结核的研究,目前已在南非,巴基斯坦安排,印度和中国。

免疫网络正在继续其对会议的合并或Immunitor类似交易完成的先决条件的工作。几个方面的最新公司及其预期交易将于2010年12月月初宣布。

免疫网络的一个临时网站在http://www.immune-network.com。免疫网络有限公司的徽标可在http://www.globenewswire.com/newsroom/prs/?pkgid=8008

安全港声明

在此发布信息,除历史资料外,可能被视为前瞻性的私人证券诉讼改革法案1995年的规定声明。投影和其他前瞻性声明和管理层的预期对未来事件和/或本公司的财务表现 - 尽管给予真诚 - 本身具有不确定性,实际事件和/或结果可能大不相同。

本新闻稿分发了商业电讯,www.globenewswire.com

来源:免疫网络有限公司

联系方式:免疫网络有限公司
[email protected]




(C)版权所有2010商业电讯公司保留所有权利。

                                                               

Rank: 10Rank: 10Rank: 10

现金
14952 元 
精华
帖子
8579 
注册时间
2008-4-12 
最后登录
2024-5-31 
2
发表于 2010-12-1 23:31 |只看该作者
www.ekomed.com.ua/catalog/catalog_en.php
DZHERELO

Composition: aqueous alcohol extract of Aloe leaves, common Knotgrass herb, Yarrow herb, Purple Coneflower, St. John's Wort, Centaury herb, Snowball tree berries, Nettle leaves, Dandelion roots, Rhizome of sweet-sedge, Oregano, Marigold flowers, Seabuckthorn fruit, Roots of Elecampane, Tormentil rootstock, Greater plantain leaves, Common wormwood herb, Siberian Golden root, Licorice root, Сottonweed herb, Common fennel, Birch tree fungus, Thyme herb, Threelobe Beggarticks herb, Sage, Dog rose fruit, Juniper fruit .

It has been shown clinically that immunomodulator Dzherelo has superior normalizing and restoring action on the immune system. Even patients with compromised immune system (including those with HIV and AIDS) do not fall ill with flu or cold. Moreover, they lose herpetic appearance of skin rash, staphylococcal abscesses and manifestations of candidiasis (fungal) lesions of mucous surfaces, while size of their lymph nodes will normalize.

When taking Dzherelo as a preventive measure it may prevent to fall ill with common cold and infectious viral diseases. It is also effective in children despite physiological immaturity of the immune system. Owing to comprehensive strengthening of the host defenses Dzherelo provides safe and effective means for treatment of flu, acute respiratory disease, hepatitis, tuberculosis, meningitis, enteric infection, neuroinfection, herpes, candidiasis, chlamidiosis and other infectious diseases.

Dzherelo normalizes the number of lymphocytes and their subpopulations' composition (ratio of T-helper and T-suppressor cells), regulatory mechanisms of immunity, regulates their activity and production of monokines and lymphokines, normalizes antibody-forming function according to types of immunoglobulins.

Moreover Dzherelo has moderate anti-stress, antineoplastic and profound anti-radiation, reparative and antioxidant effects, activates hematopoiesis, and enhances male potency. Topically Dzherelo can intensify processes of healing and reduces inflammations of wounds, trophic ulcer, pustular eruption as well as in chronic inflammatory processes (periodontosis, rhinitis, sinusitis, tonsillitis, etc.). Applications of Dzherelo in the form of liniments for 20-40 minutes will relieve manifestations of otitis, cholecystitis, cystitis.

Take 50-70 drops per 100 ml of water 1-2 times daily. External application: instill into nose and eyes – 1 dose of phytoconcentrate per 6 doses of water 3-6 times a day. For rinsing the mouth and throat, topical applications, and liniments use 20-30 drops per one table spoon of water.

Extensive testing in clinics has not revealed any side effects caused by Dzherelo (see for general recommendations and precautions on the package).

TУ У 15.8-23732912-016:2006



DZHERELO-P

Composition: aqueous alcohol extract of Succulent aloe leaves, Birch leaves, Yarrow herb, Purple Coneflower herb, Eleutherococcus roots, Snowball tree berries, Nettle leaves, Dandelion roots, Oregano, Marigold flowers, Seabuckthorn fruit, Common wormwood herb, Siberian Golden root, Wild strawberry leaves, Сottonweed herb, Common fennel fruit, Birch tree fungus, Greater Calandine herb, Dog rose fruit, Juniper fruit .

Broad spectrum of action produced by phytoconcentrate Dzherelo (humoral and cellular immunity, innate immunity, regeneration, anti-inflammatory, and anti-radiation effects) makes it less suitable for specific purposes. Dzherelo-P acts on specific immunity which makes it possible to focus on upregulation of cellular and humoral immunity especially suitable for occasions when antibiotics and other immunosuppressive agents are deployed.

Taken together Dzherelo-P suppresses rapidly almost all bacteria in the body. It provides instant effect in viral diseases only when taking duly either as a preventive measure or at the initial stages of a disease, which guarantees timely production of specific antibodies against them.

It is recommended for prophylaxis and counteraction of acute and chronic viral and microbal infections, namely flu, acute respiratory diseases, hepatitits, tuberculosis, enteric infection, neuroinfection, herpes, candidiosis, chlamidiosis, bronchopneumonia, pyelonephritis, adnexitis, prostatitis.

Take 1-2 times a day 50-70 drops per 100 ml of water. External application: instill into nose and eyes – 1 part of phytoconcentrate per 6 parts of water 3-6 times a day. It is very effective for applications on inflamed areas - take 20-30 drops per each tablespoon of water and leave for 30 minutes.

Extensive testing in clinics of different profile has not revealed any side effects caused by Dzherelo-P (see for general instructions on the package).

TУ У 15.8-23732912-016:2006
欢迎收看肝胆卫士大型生活服务类节目《乙肝勿扰》,我们的目标是:普度众友,收获幸福。
我是忠肝义胆MP4。忠肝义胆-战友的天地
QQ群搜"忠肝义胆孰能群"加入

Rank: 10Rank: 10Rank: 10

现金
14952 元 
精华
帖子
8579 
注册时间
2008-4-12 
最后登录
2024-5-31 
3
发表于 2010-12-1 23:32 |只看该作者
草药现代化。。。
欢迎收看肝胆卫士大型生活服务类节目《乙肝勿扰》,我们的目标是:普度众友,收获幸福。
我是忠肝义胆MP4。忠肝义胆-战友的天地
QQ群搜"忠肝义胆孰能群"加入

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

4
发表于 2010-12-2 17:17 |只看该作者
回复 MP4 的帖子

MP4, thank you for looking up DZHERELO. I don't know how it is connected to V5 and Immunitor.
谢谢你找到DZHERELO详情。我不知道它是如何和Immunitor有关。

V5 is claimed to be a therapeutic HBV vaccine. It uses heatinactivated HBV antigens. I am still very skeptical about its claims. Readers should be careful.
V5自称是一个治疗性乙肝疫苗。它使用heatinactivated乙肝病毒抗原。我仍然主张持怀疑态度。读者应该非常小心。
http://www.ingentaconnect.com/content/ben/lddd/2007/00000004/00000008/art00002?crawler=true

Open Label Trial of Therapeutic Hepatitis B Vaccine V-5 Immunitor (V5)Delivered by Oral Route                                                                                       
Abstract:
                        We evaluated whether V-5 Immunitor (V5), tableted immunotherapeutic preparation comprising heatinactivated HBV antigens from pooled blood of HBV- and HCV-infected donors, may produce clinical benefit through induction of oral tolerance and reduction of immune-mediated liver injury. Once daily dose of V5 was administered per os to 10 patients with chronic hepatitis B in an open label study that lasted one month. Every patient who entered the study had elevated liver enzyme levels, which at the end of study have decreased in 100% of analyzed patients. The reduction was highly significant, from 112.4 to 44.4 U/L (P=0.00009) and 118.8 to 46.1 U/L (P=0.0032), for ALT and AST respectively. In addition, half of intent-to-treat patients who were HBV surface antigen (HBsAg) positive at study entry, became negative after one month on V5 (P=0.0098). All patients, except one, reported complete recuperation from hepatitis associated clinical symptoms present at baseline (P=0.0016). No adverse events were observed at any time. Favorable biochemical, virological and clinical responses indicate that V5 is safe and effective means for immunotherapy of chronic hepatitis B. Placebo-controlled, randomized study is required to confirm these findings.

Rank: 6Rank: 6

现金
309 元 
精华
帖子
51 
注册时间
2008-9-21 
最后登录
2017-12-7 
5
发表于 2010-12-2 19:13 |只看该作者
回复 StephenW 的帖子

We evaluated whether V-5 Immunitor (V5), tableted immunotherapeutic preparation comprising heatinactivated HBV antigens from pooled blood of HBV- and HCV-infected donors, may produce clinical benefit through induction of oral tolerance and reduction of immune-mediated liver injury. Once daily dose of V5 was administered per os to 10 patients with chronic hepatitis B in an open label study that lasted one month. Every patient who entered the study had elevated liver enzyme levels, which at the end of study have decreased in 100% of analyzed patients. The reduction was highly significant, from 112.4 to 44.4 U/L (P=0.00009) and 118.8 to 46.1 U/L (P=0.0032), for ALT and AST respectively. In addition, half of intent-to-treat patients who were HBV surface antigen (HBsAg) positive at study entry, became negative after one month on V5 (P=0.0098). All patients, except one, reported complete recuperation from hepatitis associated clinical symptoms present at baseline (P=0.0016). No adverse events were observed at any time. Favorable biochemical, virological and clinical responses indicate that V5 is safe and effective means for immunotherapy of chronic hepatitis B. Placebo-controlled, randomized study is required to confirm these findings.

他们的数据显示是一半的patients在一个月后hbsag变成了负值,这些数据如果可以重复验证的话真的很不错呀

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

6
发表于 2010-12-2 19:29 |只看该作者
回复 batibaby 的帖子

" may produce clinical benefit through induction of oral tolerance" - this sentence worries me!

Rank: 10Rank: 10Rank: 10

现金
14952 元 
精华
帖子
8579 
注册时间
2008-4-12 
最后登录
2024-5-31 
7
发表于 2010-12-2 20:26 |只看该作者
StephenW 发表于 2010-12-2 17:17
回复 MP4 的帖子

MP4, thank you for looking up DZHERELO. I don't know how it is connected to V5 and  ...

www.omicsonline.org/2157-7560/2157-7560-1-103.php
3Ekomed LLC, Ulaanbaatar, Mongolia
欢迎收看肝胆卫士大型生活服务类节目《乙肝勿扰》,我们的目标是:普度众友,收获幸福。
我是忠肝义胆MP4。忠肝义胆-战友的天地
QQ群搜"忠肝义胆孰能群"加入

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

8
发表于 2010-12-2 20:41 |只看该作者
回复 MP4 的帖子

Ok. VichaiJirathitikal and Aldar S. Bourinbaiar are the prinicipals behind V5 Immunitor. They seem to be based in Thailand and the USA, respectively. Ekomed LLC, Ulaanbaatar, Mongolia is linked because Mongolia is where Immunitor did their clinical trials.
I still urge readers to be very very cautious about their results.

Rank: 6Rank: 6

现金
309 元 
精华
帖子
51 
注册时间
2008-9-21 
最后登录
2017-12-7 
9
发表于 2010-12-2 20:49 |只看该作者
回复 StephenW 的帖子

Why?What is the accurate meaning of "induction of oral tolerance"? I am the layman of the medicine.

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

10
发表于 2010-12-2 21:05 |只看该作者
回复 batibaby 的帖子

I am a layman too. "oral tolerance" or "immune tolerance in general"  is the process by which the immune system does not attack an antigen (from Wikipedia). So how can V5 causes the body not to attack HBV and yet the body later clears the HBV?
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-6-2 14:39 , Processed in 0.017651 second(s), 12 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.